Shots:

• The ongoing P-II/III study evaluates safety- efficacy & cytokine levels of plonmarlimab as monothx. (6mg/kg) vs PBO for CRS in patients with COVID-19
• The interim analysis showed preliminary results i.e.- @day 30- higher MVF rate (83.6% vs 76.7%)- lower mortality rate (4.9% vs 13.3%)- higher recovery rates (68.9% vs 56.7%) @day 14 & (80.3% vs 70.0%) @day 30 along with shortened time to recovery & hospitalization duration
• Additionally- biomarker results were consistent with the clinical outcome & demonstrated a reduction in plasma levels of pro-inflammatory cytokines & chemokines. The company plans to continue advancing the study in the US & start to analyze in other related CRS

  | Ref: PR Newswire | Image: I-Mab